MRNA Moderna
- 117.310
- -5.380-4.39%
- 117.290
- -0.020-0.02%
Moderna News
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock -- Barron's
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter. Ed Lin America's largest public pension recently pulled back on some media
Moderna(MRNA.US) Director Sells US$1.83 Million in Common Stock
$Moderna(MRNA.US)$ Director AFEYAN NOUBAR sold 15,000 shares of common stock on May 8, 2024 at an average price of $121.6814 for a total value of $1.83 million.Source: Announcement What is statement o
S&P 500, Dow Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey
US benchmark equity indexes closed mostly higher Friday as investors evaluated remarks by Federal Reserve officials and a consumer sentiment survey. The Dow Jones Industrial Average rose 0.3% to 39,51
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks rose late Friday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each increasing 0.3%. The iShares Biotechnology ETF (IBB) added 0.1%. In
Equity Markets Mixed Intraday After Consumer Sentiment Survey
US benchmark equity indexes were mixed after midday Friday as a survey showed US consumer sentiment tumbling and inflation expectations rising. The Nasdaq Composite was down 0.2% at 16,312.9 intraday,
Trending: Moderna's Proposed RSV Vaccine Faces Delayed FDA Review
13:53 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The company said that the U.S. Food and Drug Administratio
Novavax CEO on Sanofi Deal: 'This Is a New Chapter in the History of Our Company'
Top Midday Stories: Biden to Reportedly Quadruple Chinese EV Tariffs; Novavax Shares Soar on Sanofi Deal News; Protesters Try to Break Into Tesla's Plant in Germany; FDA Pushes Back Approval of Moderna Vaccine
The major US indexes were mixed in late-morning trading Friday with the Dow Jones Industrial Average leading the charge and looking to extend its winning streak to eight days. In company news, Enbridg
Novavax Hits a 52-week High as Sanofi Deal Prompts J.P. Morgan Upgrade
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
The Food and Drug Administration (FDA) notified Moderna Inc (NASDAQ:MRNA) on Friday that its review of a new vaccine has been delayed.The agency, citing administrative constraints, does not expect to
Sector Update: Health Care Stocks Edge Higher Premarket Friday
Health care stocks were edging higher premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) recently up 0.4%. Novavax (NVAX) skyrocketed
FDA Delays Decision on Moderna RSV Shot by 3 Weeks -- Barrons.com
By Josh Nathan-Kazis The Food and Drug Administration has pushed back the release of its decision on approval of Moderna's respiratory syncytial virus vaccine by up to three weeks due to "administrat
Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
By Colin Kellaher Moderna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's proposed vaccine for respiratory syncytial virus, or
FDA Delays Approval of Moderna's RSV Vaccine
07:25 AM EDT, 05/10/2024 (MT Newswires) -- FDA Delays Approval of Moderna's RSV Vaccine Price: 119.50, Change: -3.19, Percent Change: -2.60
Moderna said the US Food and Drug Administration will not complete the review of “mRNA-1345” before May 12. Moderna fell 1.5% before the market.
Moderna said the US Food and Drug Administration will not complete the review of “mRNA-1345” before May 12. Moderna fell 1.5% before the market.
FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12
FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12
Moderna Says FDA Delayed RSV Vaccine Approval to End of May
Moderna said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end of May due to "administrative constraints" at the agency. The FDA was expected to make a decision on the RSV shot on Sunday. The agency has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said in a release.
Moderna Announces Update on Investigational RSV Vaccine
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024Agency has indicated it expects to complete the review by end of
US FDA Pushes Decision on Moderna's RSV Vaccine to End of This Month
The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...
① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.
Analysis
Price Target
No Data
